Cabazitaxel

Drug Profile

Cabazitaxel

Alternative Names: 116,258; Jevtana; RPR 116258; RPR 116258A; Taxoid-116258; TXD 258; XRP6258

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer AIO Studien gGmbH; Bristol Haematology and Oncology Centre; European Organisation for Research and Treatment of Cancer; German Breast Group; Sanofi; University Hospitals Bristol NHS Foundation Trust
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Brain metastases; Breast cancer; Germ cell and embryonal neoplasms; Liposarcoma; Penile cancer; Small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Gastric cancer; Head and neck cancer

Most Recent Events

  • 12 Dec 2016 Scottish Medicines Consortium approves cabazitaxel for prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater)
  • 07 Oct 2016 Adverse events data from the phase III FIRSTANA trial in Prostate cancer presented at the 41st European Society for Medical Oncology Congress (ESMO - 2016)
  • 16 Aug 2016 Erasmus Medical Center in collaboration with Sanofi withdraws the phase II CARVE trial in Prostate cancer (Metastatic disease, Second-line or greater therapy) prior to enrolment in the Netherlands (NCT02621190)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top